Industry Analysis: Universal Pharmacy Ltd

1. Industry Classification

Sector: Community Pharmacy (SIC 47730 – Dispensing chemist in specialised stores)

Key Sector Characteristics: The UK community pharmacy sector operates within a highly regulated framework governed by NHS contractual arrangements, General Pharmaceutical Council (GPhC) oversight, and Department of Health & Social Care (DHSC) funding agreements. The sector is characterised by:

• Revenue composition: Predominantly NHS-funded through the Pharmaceutical Services Negotiating Committee (PSNC) contractual framework, with dispensing margins, National Health Service (NHS) fees, and Quality Payments Scheme income forming the core revenue streams. Typical independent pharmacies derive 85-90% of turnover from NHS-related activity.

• Margin structure: Historically thin net margins of 2-3% for independent operators, with gross dispensing margins typically 20-25% before operating costs. The sector has faced sustained margin erosion since the 2016 funding cuts.

• Capital intensity: Moderate, with significant working capital tied to pharmaceutical stock (controlled drugs and high-cost medicines can require substantial inventory investment), fittings and fixtures, and increasingly technology infrastructure for Electronic Prescription Service (EPS) and hub-and-spoke models.

• Regulatory barriers: Entry requires GPhC registration, superintendent pharmacist oversight, and NHS contractual approval – creating natural barriers but also compliance costs.

2. Relative Performance

Balance Sheet Analysis Against Sector Norms

Critical Observations:

The trajectory from net assets of £272,227 (FY2021) to £6,649 (FY2022) represents a 97.6% erosion of shareholder value in a single year. This is far beyond typical sector volatility. The accumulated losses of (£267,542) against share capital of £274,191 leave virtually no equity cushion – a position that would place this pharmacy in the bottom decile of community pharmacy balance sheets.

The retained earnings movement from (£1,964) to (£267,542) implies a trading loss of approximately £265,578 for FY2022 – an extraordinary figure for a single pharmacy operation. For context, the average independent community pharmacy generates pre-tax profits of approximately £30,000-£40,000 annually (PSNC/Leyton data), making this loss approximately 6-7 times typical annual earnings.

Working Capital Crisis

The swing from net current assets of £112,309 to net current liabilities of (£302,746) represents a £415,055 deterioration in working capital. This is particularly concerning in a sector where:

• Stock represents the primary current asset (pharmaceutical inventory)
• Trade debtors typically include significant NHS receivables
• Current creditors often include Drug Tariff reimbursement obligations and wholesaler accounts

The stock increase from £238,104 to £425,942 (79% rise) may indicate: 1. Stockpiling of high-cost medicines 2. Potential overstocking or slow-moving inventory 3. Possible expansion of dispensing volume (though not necessarily profitably)

Asset Composition

Total assets of £2.4m for a single pharmacy is substantially above sector norms (typical range £300k-£800k). The fixed asset base of £1.05m is particularly notable – this likely includes leasehold improvements, fittings, and potentially property. The depreciation policy of "10% reducing balance and 2% on cost" for plant and machinery is standard for the sector.

3. Sector Trends Impact

Structural Headwinds Affecting Universal Pharmacy

NHS Funding Compression: The community pharmacy funding settlement has seen real-terms reductions of approximately 30% since 2015/16. The five-year Community Pharmacy Contractual Framework (CPCF) 2019-2024 shifted emphasis from dispensing volume to service provision, but transitional funding reductions have squeezed margins. Universal Pharmacy's FY2022 period (April 2021-March 2022) coincided with the post-pandemic funding cliff edge, where COVID-19 support payments were tapering whilst cost pressures were accelerating.

Margin Erosion Mechanisms: - Category M pricing adjustments: Quarterly Drug Tariff revisions have systematically reduced generic margins, with the DHSC targeting a £800m margin delivery per annum. For a pharmacy of this scale, even modest Category M adjustments can eliminate annual profitability. - Concessionary pricing volatility: Where branded medicines face supply issues, concessionary prices may fall below purchase cost, creating negative margins.

Inflationary Pressure Wave (2021-22): FY2022 captured the onset of significant cost inflation: - Energy costs rising 50-100% for pharmacy premises - Wage inflation following National Living Wage increases and pharmacist recruitment crises (vacancy rates reached 16% in community pharmacy per Company Chemists' Association data) - Wholesale price inflation on pharmaceutical inputs - Business rates revaluations in England

Competitive Disruption: - Online pharmacy penetration: Platforms such as Pharmacy2U and LloydsDirect have captured significant repeat prescription market share, estimated at 15-20% of NHS dispensing volume in some areas - Consolidation: Multiple operators (Well, Lloyds, Boots) have leveraged scale advantages, whilst corporate consolidation has accelerated – the Hub & Spoke regulatory framework enabling centralised dispensing threatens independent margins further - Supermarket pharmacy competition: In-store pharmacies benefit from cross-subsidisation and footfall

Regulatory Burden: - GPhC inspection regime costs - Falsified Medicines Directive (FMD) compliance (though suspended during period) - Controlled drugs governance requirements - Data protection and information governance obligations

4. Competitive Positioning

Strengths

1. Established presence: Trading since 2011, suggesting established patient list and local market position – critical in a sector where 80% of revenue derives from repeat prescriptions tied to registered patient nominations.

2. Significant asset base: The £2.4m total asset position, particularly the £1.05m in fixed assets, may indicate property ownership or substantial leasehold interests – a differentiator from many pharmacy tenants operating from leased premises with limited tangible asset backing.

3. Family ownership structure: The Sarwar family control via Upl Holdings Ltd provides strategic stability and long-term orientation, avoiding the short-termism that can afflict corporately-owned pharmacies. Family-run pharmacies typically demonstrate greater resilience during funding downturns.

4. Improved cash position: The increase in cash from £6,011 to £151,437 suggests either improved cash management, drawdown of facilities, or asset disposals – though this must be viewed alongside the dramatic liability increase.

Weaknesses

1. Critically impaired solvency: Net assets of £6,649 on a £2.4m balance sheet represents a gearing ratio of approximately 249:1 (liabilities to equity) – far exceeding the sector norm of 3:1 to 5:1. This positions the company in the highest risk category for financial distress.

2. Working capital deficit: Net current liabilities of £302,746 indicate the business is technically insolvent on a current basis – current liabilities exceed current assets. In pharmacy terms, this likely means NHS and wholesaler creditors exceed the realisable value of stock and debtors.

3. Overdue statutory filings: Both accounts and confirmation statement are overdue, suggesting potential governance or administrative stress – a concerning signal for a GPhC-registered pharmacy where "fitness to practise" encompasses financial probity.

4. Single-director dependency: With Nadeem Ahmed Sarwar as the sole director, there is key-person risk and potential challenges meeting the GPhC requirement for adequate governance arrangements.

5. Scale limitations: As a single-outlet independent, Universal Pharmacy lacks the procurement leverage, operational efficiencies, and service diversification available to multiples. Average operating costs per prescription are typically 15-20% higher for independents versus chains.

Comparative Context

Against typical independent community pharmacy financials:

The financial profile is consistent with a business that has over-expanded into fixed assets (possibly property acquisition or major refit) funded through debt, whilst experiencing severe trading deterioration. The £741,516 increase in total liabilities year-on-year, against only £426,864 growth in total assets, indicates the business is leveraging beyond its capacity to service.

Going Concern Assessment

The accounts include a going concern statement, which is standard but notable given the financial position. The directors' assertion that they have "reasonable expectation" of adequate resources would typically require evidence of: - Bank facility renewals or extensions - Director/shareholder support letters - Cash flow forecasts demonstrating viability - Potential restructuring of creditor obligations

Without visibility of these supporting arrangements, the going concern basis appears challenged under FRS 102 requirements.